Skip to main content
. Author manuscript; available in PMC: 2012 Dec 1.
Published in final edited form as: J Hepatol. 2011 Apr 14;55(6):1281–1290. doi: 10.1016/j.jhep.2011.03.017

Figure 7. The expression of EGFR is increased in the cPLA2α transgenic mice. The effect of the cPLA2α inhibitor (pyrrolidine).

Figure 7

The cPLA2α Tg and wild type mice were treated intraperitoneally with vehicle (DMSO) or pyrrolidine (3 mg/kg) and animals were sacrificed at 4 hours after injection. The liver tissues were then homogenized to extract mRNA for real time quantitative PCR (qPCR) and protein for Western blotting analysis. (A) Real time quantitative PCR (qPCR) showed increased EGFR mRNA level in the cPLA2α Tg mice compared to the wild type mice. Treatment with the cPLA2α inhibitor, pyrrolidine, significantly reduced EGFR mRNA level. The data are presented as Mean + SD (n = 3, *p<0.01). (B) Western blot analysis showed reduced level of EGFR protein in mice treated with pyrrolidine.